Latest Pharma Insights
Deals In Depth: May 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026
US Supplement Industry Questions Sources For Texas AG’s ‘Harmful Ingredients’ Investigation
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026
BIO 2026 Preview: Deals And Finance, AI And Regulatory Trends Are Top Of Mind
The annual BIO International Convention gives biopharma firms a chance to engage with potential partners while taking stock of the industry climate at mid-year.
Scrip - June 17, 2026
The annual BIO International Convention gives biopharma firms a chance to engage with potential partners while taking stock of the industry climate at mid-year.
Scrip - June 17, 2026
Novo Nordisk Sees The Future Of Diabetes Care As Individualized
Novo’s chief medical officer talked to Scrip about the direction diabetes and obesity treatment is going and the potential benefits of its dual GLP-1/amylin agonists CagriSema and zenagamtide.
Scrip - June 17, 2026
Novo’s chief medical officer talked to Scrip about the direction diabetes and obesity treatment is going and the potential benefits of its dual GLP-1/amylin agonists CagriSema and zenagamtide.
Scrip - June 17, 2026
AbCellera Finds Latest Antibody Discovery Partner In Jazz
Deal Snapshot: Jazz joins a who’s who list of biopharmaceutical companies that have enlisted AbCellera’s technology to find novel antibodies against challenging targets.
Scrip - June 17, 2026
Deal Snapshot: Jazz joins a who’s who list of biopharmaceutical companies that have enlisted AbCellera’s technology to find novel antibodies against challenging targets.
Scrip - June 17, 2026
FDA Pendulum Swing Means A Green Light For UniQure AMT-130
In a reversal, the US FDA agreed the company can file AMT-130 for accelerated approval based on a Phase I/II trial. The company’s stock price surged 79% in midday trading.
Scrip - June 17, 2026
In a reversal, the US FDA agreed the company can file AMT-130 for accelerated approval based on a Phase I/II trial. The company’s stock price surged 79% in midday trading.
Scrip - June 17, 2026
GSK’s Utebzi Marks First Oral Carbapenem Antibiotic
The US FDA approved tebipenem pivoxil for complicated urinary tract infections, providing an alternative to intravenous treatments requiring hospitalization.
Scrip - June 17, 2026
The US FDA approved tebipenem pivoxil for complicated urinary tract infections, providing an alternative to intravenous treatments requiring hospitalization.
Scrip - June 17, 2026
Lilly Packs Pain Pipeline With 4E Therapeutics Purchase
Another day and another deal for the cash-rich US giant.
Scrip - June 17, 2026
Another day and another deal for the cash-rich US giant.
Scrip - June 17, 2026
Luye’s Novel Tardive Dyskinesia Contender Aces Phase II Trial
Luye's first-in-class VMAT2/Sigma-1 receptor-targeted molecule achieves a 76.5% response rate in a Phase II trial for tardive dyskinesia.
Scrip - June 17, 2026
Luye's first-in-class VMAT2/Sigma-1 receptor-targeted molecule achieves a 76.5% response rate in a Phase II trial for tardive dyskinesia.
Scrip - June 17, 2026
Korean Novel Early-Stage Assets Intensify Global Obesity Race
South Korean biopharma companies are advancing and expanding their obesity drug pipelines, with a focus on next-generation approaches including multi-target agonists, muscle-preserving therapies and oral formulations.
Scrip - June 17, 2026
South Korean biopharma companies are advancing and expanding their obesity drug pipelines, with a focus on next-generation approaches including multi-target agonists, muscle-preserving therapies and oral formulations.
Scrip - June 17, 2026
Progress For J-Pharma’s First-In-Class LAT1 Inhibitor After FDA ‘Alignment’
Academic research-based Japanese venture kicks off pivotal clinical development phase for novel therapy for high-need indication.
Scrip - June 17, 2026
Academic research-based Japanese venture kicks off pivotal clinical development phase for novel therapy for high-need indication.
Scrip - June 17, 2026
New Maggot Species Cleared For Wound Care
The US FDA has issued a 510(k) clearance to Cuprina for MEDIFLY Maggots, the first line of medical-grade Lucilia cuprina larvae authorized for use in maggot debridement therapy.
Medtech Insight - June 17, 2026
The US FDA has issued a 510(k) clearance to Cuprina for MEDIFLY Maggots, the first line of medical-grade Lucilia cuprina larvae authorized for use in maggot debridement therapy.
Medtech Insight - June 17, 2026
Draft CMS TAVR Memo ‘Clear Win’ For Edwards But Leaves Regurgitation Players Waiting
CMS has proposed expanding TAVR coverage to include patients with asymptomatic severe aortic stenosis, which analysts called a clear win for Edwards Lifesciences. The draft NCD stops short of addressing TAVR treatment for pure aortic regurgitation.
Medtech Insight - June 17, 2026
CMS has proposed expanding TAVR coverage to include patients with asymptomatic severe aortic stenosis, which analysts called a clear win for Edwards Lifesciences. The draft NCD stops short of addressing TAVR treatment for pure aortic regurgitation.
Medtech Insight - June 17, 2026
Solius Labs Launches Solius Pro, The First FDA-Cleared OTC UVB Therapy Device
A new FDA product code and $2,995 consumer-direct price, with no insurance required, position Solius Labs' personalized UVB panel as a scalable alternative to clinic-based phototherapy.
Medtech Insight - June 17, 2026
A new FDA product code and $2,995 consumer-direct price, with no insurance required, position Solius Labs' personalized UVB panel as a scalable alternative to clinic-based phototherapy.
Medtech Insight - June 17, 2026
Cardiac Monitor Maker iRhythm Hit By Data Breach And Extortion Demand
Hackers exfiltrated patient health information and proprietary data from iRhythm Technologies and demanded payment for silence, the cardiac monitoring company disclosed in a June 15 SEC filing – the latest in a string of cyberattacks targeting medtech and healthcare firms in 2026.
Medtech Insight - June 17, 2026
Hackers exfiltrated patient health information and proprietary data from iRhythm Technologies and demanded payment for silence, the cardiac monitoring company disclosed in a June 15 SEC filing – the latest in a string of cyberattacks targeting medtech and healthcare firms in 2026.
Medtech Insight - June 17, 2026
MHRA Gets Closer To GB Regulation And Touts US FDA Partnership As Industry Eyes EU MDR Changes
Significant regulatory change lies ahead for manufacturers serving the UK and the EU medtech markets, but in the lull before the storm, they must bide their time and respond to MHRA and European Commission surveys – while keeping a close watch on UK/US collaboration efforts.
Medtech Insight - June 17, 2026
Significant regulatory change lies ahead for manufacturers serving the UK and the EU medtech markets, but in the lull before the storm, they must bide their time and respond to MHRA and European Commission surveys – while keeping a close watch on UK/US collaboration efforts.
Medtech Insight - June 17, 2026
US Supplement Industry Questions Sources For Texas AG’s ‘Harmful Ingredients’ Investigation
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026
“Far too many corporations have snuck harmful ingredients in their products,” says Texas AG and GOP Senate nominee Ken Paxton. “The importance of grounding regulatory action in sound science is illustrated by a cautionary precedent,” cautions NPA.
HBW Insight - June 18, 2026
Organon Adds Two New Indications For Its Actemra Biosimilar Rival
Organon closes an indication gap with Tofidence, but subcutaneous availability and market share remain areas where its tocilizumab biosimilar still lags behind.
Generics Bulletin - June 17, 2026
Organon closes an indication gap with Tofidence, but subcutaneous availability and market share remain areas where its tocilizumab biosimilar still lags behind.
Generics Bulletin - June 17, 2026
Who’s Hired? Teva’s TAPI Taps Regev As CCO
Teva’s TAPI active pharmaceutical ingredients business has named a new chief commercial officer, while other firms including Perrigo, Phlow, CNX, Adalvo, Rezon Bio and Sandoz have also announced leadership updates.
Generics Bulletin - June 17, 2026
Teva’s TAPI active pharmaceutical ingredients business has named a new chief commercial officer, while other firms including Perrigo, Phlow, CNX, Adalvo, Rezon Bio and Sandoz have also announced leadership updates.
Generics Bulletin - June 17, 2026
Saudi Arabia Joins Global Push To Streamline Biosimilars
Saudi Arabia has finalized biosimilar guidance setting out when strong analytical and PK evidence may replace comparative efficacy trials, aligning the SFDA with a broader global shift toward streamlined biosimilar development.
Generics Bulletin - June 17, 2026
Saudi Arabia has finalized biosimilar guidance setting out when strong analytical and PK evidence may replace comparative efficacy trials, aligning the SFDA with a broader global shift toward streamlined biosimilar development.
Generics Bulletin - June 17, 2026
Deals In Depth: May 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026
Seven $1bn+ alliances were penned in May, and three exceeded $2bn (two of those werein excess of 11 figures). In the top alliance by deal value, Hengrui Pharma?and?Bristol Myers Squibb entered into a potential $15.2bn global collaboration to advance a portfolio of 13 early-stage programs.
In Vivo - June 18, 2026